Ipsen voluntary admission: employee promoted to HCPs in Northern Ireland without verified ABPI representative exam (AUTH/3839/10/23)

📅 8 March 2026 | 🖉 Dr Anzal Qurbain
📊

Key facts

Case numberAUTH/3839/10/23
CompanyIpsen Limited
Case typeVoluntary admission
IssueFailure to verify/passage of ABPI medical representative examination for an employee calling on HCPs in Northern Ireland
GeographyNorthern Ireland (employee previously in Ireland-only role)
Applicable Code (Panel applied)2019 Code (Clauses 9.1 and 16.3)
Breach clausesClause 9.1; Clause 16.3
SanctionsUndertaking received; Additional sanctions: Not stated
Complaint received16 October 2023
Case completed18 September 2024
AppealNo appeal

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
📋

What happened

  • Ipsen identified (via an internal audit) that one employee in a promotional, customer-facing role calling on health professionals in Northern Ireland had no ABPI representative exam certificate on file and the ABPI could not confirm completion.
  • The employee had moved internally from an Ireland-only promotional role (not subject to ABPI representative exam requirements) to a Northern Ireland promotional role in January 2019.
  • The employee had been calling on customers for over 15 months without Ipsen verifying the required qualification and without applying for any training exemption.
  • On discovery (April 2020), Ipsen instructed the employee to cease all promotional activity and work only in a non-promotional capacity.
  • Ipsen submitted a voluntary admission to the PMCPA in October 2023.
  • Ipsen updated SOPs/processes so HR would check and record ABPI exam certificates for new starters and for employees transitioning into promotional roles (including contractors providing temporary cover).
⚖️

Outcome

  • Breach of Clause 16.3 (2019 Code) ruled (as acknowledged by Ipsen).
  • Breach of Clause 9.1 (2019 Code) ruled due to lack of robust process/due diligence when employees transferred roles and concerns about onboarding robustness.
  • No appeal.
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

⭐ Charter Member — Until 31 March

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export. £1,999/year £2,499

Get Charter Access →

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free